Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N -Acetylcysteine) Supplementation

• Published in: Antioxidants Vol. 11; no. 1; p. 50
• Main Authors: Kumar, Premranjan, Osahon, Ob, Vides, David B, Hanania, Nicola, Minard, Charles G, Sekhar, Rajagopal V
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.12.2021; MDPI
• Subjects: Acetylcysteine; Age; Age groups; Antioxidants; Biochemistry; Blood; Clinical trials; Coronaviruses; COVID-19; COVID-19 vaccines; Creatinine; Diabetes; Disease; Glutathione; GlyNAC; Health care; Hospitalization; Hospitals; Hypotheses; Middle age; Mortality; Older people; oxidant damage; Oxidants; Oxidative stress; Pandemics; Patients; Physiology; Plasma; Reactive oxygen species; Severe acute respiratory syndrome coronavirus 2; Supplements; Young adults; United States > US; COVID-19; oxidant damage; glutathione; GlyNAC; oxidative stress
• ISSN: 2076-3921; 2076-3921
• DOI: 10.3390/antiox11010050

Humanity is battling a respiratory pandemic pneumonia named COVID-19 which has resulted in millions of hospitalizations and deaths. COVID-19 exacerbations occur in waves that continually challenge healthcare systems globally. Therefore, there is an urgent need to understand all mechanisms by which COVID-19 results in health deterioration to facilitate the development of protective strategies. Oxidative stress (OxS) is a harmful condition caused by excess reactive-oxygen species (ROS) and is normally neutralized by antioxidants among which Glutathione (GSH) is the most abundant. GSH deficiency results in amplified OxS due to compromised antioxidant defenses. Because little is known about GSH or OxS in COVID-19 infection, we measured GSH, TBARS (a marker of OxS) and F2-isoprostane (marker of oxidant damage) concentrations in 60 adult patients hospitalized with COVID-19. Compared to uninfected controls, COVID-19 patients of all age groups had severe GSH deficiency, increased OxS and elevated oxidant damage which worsened with advancing age. These defects were also present in younger age groups, where they do not normally occur. Because GlyNAC (combination of glycine and -acetylcysteine) supplementation has been shown in clinical trials to rapidly improve GSH deficiency, OxS and oxidant damage, GlyNAC supplementation has implications for combating these defects in COVID-19 infected patients and warrants urgent investigation.